Role of Endothelin-1 in the Migration of Human Olfactory Gonadotropin-Releasing Hormone-Secreting Neuroblasts

Roberto G. Romanelli, Tullio Barni, Mario Maggi, Michaela Luconi, Paola Failli, Anna Pezzatini, Annamaria Morelli, Roberto Maggi, Roberta Zaninetti, Roberto Salerno, Stefano Ambrosini, Mirca Marini, Carlo M. Rotella, and Gabriella B. Vannelli

Departments of Anatomy Histology and Forensic Medicine (A.P., S.A., M.M., G.B.V.), Clinical Physiopathology and Endocrinology (R.S., C.M.R.), and Andrology Units (M.M., M.L., A.M.), Internal Medicine (R.G.R.), and Preclinical and Clinical Pharmacology (P.F.), University of Florence, I-50134 Florence; Department of Endocrinology (R.M., R.Z.), University of Milan, 20133 Milan; and Experimental and Clinical Medicine (T.B.), University of Catanzaro, 88100 Catanzaro, Italy

FNC-B4 neuroblasts that express both neuronal and olfactory markers have been established and cloned. These cells express GnRH and both the endothelin-1 (ET-1) gene and protein and respond in a migratory manner to GnRH in a dose-dependent manner. Previous research has shown that FNC-B4 cells produce and respond to ET-1 by regulating the secretion of GnRH through endothelin type A receptors and by stimulating their proliferation through endothelin type B (ETB) receptors. In this study, we found that FNC-B4 cells are able to migrate in response to ET-1 through the involvement of ETB receptors. Combined immunohistochemical and biochemical analyses showed that ET-1 triggered actin cytoskeletal remodeling and a dose-dependent increase in migration (up to 6-fold). Whereas the ETB receptor antagonist (B-BQ788) blunted the ET-1-induced effects, the ETA receptor antagonist (A-BQ123) did not. Moreover, we observed that FNC-B4 cells were independently and selectively stimulated by ET-1 and GnRH. We suggest that ET-1, through ETB receptor activation, may be required to maintain an adequate proliferative stem cell pool in the developing olfactory epithelium and the subsequent commitment to GnRH neuronal migratory pattern. The coordinate interaction between ET receptors and GnRH receptor participates in the fully expressed GnRH-secreting neuron phenotype. (Endocrinology 146: 4321–4330, 2005)

HOW CELLS INITIATE, maintain, and stop their migration remains a fascinating problem in many developmental systems. Although the GnRH-secreting neurons are located postnatally within the forebrain, during embryogenesis, they arise from the olfactory placode and then migrate into the hypothalamus (1, 2). Proper spatio-temporal expression of transcription factors plays a crucial role in these processes, both in guiding GnRH-secreting neurons during their migration and in orchestrating their subsequent differentiation (3). Although the endothelin (ET) family was initially characterized as potent vasoactive peptides, a variety of other biological functions were subsequently discovered, such as stimulation of hormone release and regulation of central nervous system activity (4–7). In particular, ET immunoreactivity (8) and ET receptors (9) are present in median eminence and arcuate nucleus, in which GnRH neurons are mostly concentrated. Interestingly, ET peptides stimulate GnRH release from hypothalamic explants (10), fetal rat hypothalamic neurons (11), and fetal human olfactory cells (12).

Recent gene-inactivation studies of the components of the ET pathway have revealed some other unexpected roles of these peptides, especially during mammalian development. Mice deficient in endothelin-1 (ET-1), endothelin type A (ETA) receptor, and endothelin-converting enzyme-1 have defects in the development of subsets of cephalic and cardiac neural crest derivatives, including branchial arch-derived craniofacial tissues, and great vessel and cardiac outflow structures (13–16). Mice deficient in endothelin-3 (ET-3) or endothelin type B (ETB) receptor show spotted coat color and aganglionic megacolon due to defects in the development of neural crest-derived melanocytes and enteric neurons, respectively (17, 18). In humans, multigenic Hirschsprung’s disease, or congenital aganglionosis of the distal gut, is caused by a failure of the neural crest cells to form ganglia in the distal part of the gut. This disease is characterized by pigmentation defects, deafness, and megacolon (19–21). New insights into the pathogenesis and the molecular basis of this abnormality in humans have been gained from the identification of certain critical genes, such as ET-3 and the ETB receptor in mice. These genes play a role in the development of the peripheral nervous system and in that of the connective tissue in the face, neck, and heart (22, 23). Recent research has demonstrated that genetic interactions between mutations in receptor for glial-derived neurotrophic factors (RET, receptor protein tyrosine kinase) and the ETB receptor is one of the underlying mechanisms for this complex dis-
order (24). Furthermore, the interaction between the RET and ETB receptor loci in humans and mice regulates enteric nervous system development in the distal colon. It also regulates the coordinated and balanced interaction between RET and ETB receptor signaling pathways and controls the development of the mammalian enteric nervous system throughout the intestine (25). Recently, it has been demonstrated that temporally distinct requirements for ETB receptor occur in the proliferation and migration of gut neural crest stem cells (26). In a previous research, we showed that GnRH-secreting neurons, FNC-B4 cells, produce and respond to ET-1 and that this peptide regulates GnRH-secretion or cell proliferation, depending on which subtype of the ET receptor is activated (12). Moreover, GnRH acts in an autocrine/paracrine pattern to promote migration of FNC-B4 neuroblasts (27). The aim of this study was to elucidate the role played by ET-1 in the migratory pattern of GnRH-secreting neurons. FNC-B4 cells dose dependently migrated in response to ET-1 through the involvement of ETB receptor. We also report that GnRH and ET-1 act in a biologically independent and selective manner, and their recruitment is able to elicit a functional crosstalk during migration.

Materials and Methods

Cell cultures

The primary human GnRH-secreting neuronal cell line, FNC-B4 cells, has been established, cloned, and propagated in vitro from the fetal olfactory system and cryogenically preserved. FNC-B4 cells have been phenotypically, biochemically, and functionally characterized (12, 27–31). These cells grow as a monolayer, are non-tumorigenic, and have a normal human karyotype. The immortalized GnRH-expressing neuronal cell line, GN11 cells, was used in some experiments (generously provided by S. Radovick, University of Chicago, Chicago, IL). GN11 neuronal cells have been isolated from olfactory bulb tumors of migratory pattern of GnRH-secreting neurons. FNC-B4 cells dose dependently migrated in response to ET-1 through the involvement of ETB receptor. We also report that GnRH and ET-1 act in a biologically independent and selective manner, and their recruitment is able to elicit a functional crosstalk during migration.

Chemicals

$[^{252}]$I-GnRH (2200 Ci/mmol) was obtained from PerkinElmer Life Science Products (Milan, Italy). $[^{3}H]$ET-1 (2000 Ci/mmol) was purchased from Amersham Biosciences (Amity PG, Milan, Italy). A GnRH RIA kit was obtained from Buhlmann Laboratories (Allschwil, Switzerland). Unlabeled ET-1 and the ETA-selective antagonist A-BQ123 were obtained from NovaBiochem (Lauffenfingen, Switzerland). The ETB-selective agonist IRL-1620 and antagonist B-BQ788 were purchased from Alexis (Lauffenfingen, Switzerland). The polyclonal antibodies to ET-1 (RAS 6901) were purchased from Peninsula Laboratories (San Carlos, CA). Synthetic GnRH was obtained from Incostar (Stillwater, MN). GnRH agonist buserelin (n-tet-butyl-Ser6-des-Gly10-Pro9-ethylamide-GnRH) was purchased from Sigma (St. Louis, MO). GnRH antagonist cetorelix [Ac-d-Nal(2), d-Phe(4)C2, d-Pal(3), d-Cit(6), d-Ala(10)] was purchased from ASTA Medica (Frankfurt, Germany). The rabbit polyclonal antibodies to the ETA and ETB receptors were provided by Assay Design (Ann Arbor, MI) and were used at 1:100 concentration; the antiogt polyclonal neuron-specific enolase (NSE) antibody (1:100 dilution) sc-7455 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 3,4,3′,4′-Tetra-aminoindophenylhydrazide chloride (diaminobenzidine) was obtained from BDH Chemicals (Poole, UK). Streptavidin-biotin peroxidase complex kits were obtained from Dako (Carpinteria, CA). Other reagents were obtained at the highest grade available from commercial sources or from Sigma.

Isolation of RNA and cDNA synthesis

Total RNA was extracted from cells using RNAase mini kit from Qiagen (Valencia, CA) according to the instructions of the manufacturer. RNA concentration and quality were measured by spectrophotometric analysis at 260 and 280 nm. RNA integrity was assessed by electrophoresis in agarose gel. Total RNA (400 ng) was reverse transcribed to cDNA in a final volume of 80 μl using TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, CA) at the following conditions: 10 min at 25 C, 30 min at 48 C, and 5 min at 95 C.

Real-time quantitative RT-PCR

The mRNA quantitative analysis was performed according to the fluorescent TaqMan methodology, as published previously (36). PCR primers and probe for mRNA quantitation of ET-1 receptors (ETA and ETB) were purchased as an assay-on-demand (AOD) gene expression product from Applied Biosystems. The glycerolaldehyde-3-phosphate dehydrogenase gene was chosen as the reference gene, and the corresponding AOD product was provided by Applied Biosystems. The PCR mixture (25 μl final volume) consisted of 1× final concentration of AOD mix, 1× final concentration of Universal PCR Master mix (Applied Biosystems), and 25 ng cDNA. Amplification and detection were performed with an ABI Prism 7700 Sequence Detection System (version 1.7) (Applied Biosystems) with the following thermal cycle conditions: 2 min at 50 C, 10 min at 95 C, and 40 cycles at 95 C for 30 sec and 60 C for 1 min. Each measurement was performed in duplicate. mRNA quantitation was based on the comparative $ΔC_T$ method, according to the instructions of the manufacturer, in which $C_T$ represents the cycle number at which the fluorescent signal, associated with an exponential increase in PCR products, crossed a given threshold. The maximum change in $C_T$ values of the sample ($ΔC_T$ sample) was determined by subtracting the average of duplicate $C_T$ values of the reference gene from the average of the duplicate $C_T$ values of the target gene. Human umbilical vascular endothelial cells (HUVEC) (37), classically considered positive targets for ETB ligands, together with the SH-SY5Y cell line, were used as controls.

Measurement of intracellular calcium concentration

Digital video imaging of the intracellular-free calcium concentration ($[Ca^{2+}]_i$) in individual human FNC-B4 cells was performed as described previously (27). Human neurons were grown to subconfluence in complete culture medium on round glass coverslips (25-mm diameter, 0.2-mm thick) for 72 hr and then incubated for 48 hr in serum-free medium (SMF) at 37 C. Cells were then loaded with 10 μmol/l fura 2-AM and 15 μM Pluronic F-127 for 30 min at 22 C. $[Ca^{2+}]_i$ was measured in fura 2-loaded cells in HEPES-NaHCO3 buffer containing the following (in mmol/l): 140 NaCl, 3 KCl, 0.5 NaH2PO4, 12 NaHCO3, 1.2 MgCl2, 1.0 CaCl2, 10 HEPES, and 10 glucose (pH 7.4). Ratio images (340/380 nm) were collected every 3 sec, and calibration curves were obtained for each cell preparation. ET-1, ETA, and ETB receptor antagonists (A-BQ123 and B-BQ788), GnRH and/or its analog (buserelin), and GnRH antagonist (cetorelix) (from 0.1 μM to 10 nm) were directly added to the perfusion chamber immediately after recording the $[Ca^{2+}]_i$ basal value. In parallel experiments, cells were preincubated with 0.1 μM ETB receptor antagonist for 10 min before addition of ET-1. These experiments were done in triplicate.

Immunocytochemical procedures and confocal laser microscopy

FNC-B4 cells were cultured on glass coverslips in SFM for 18 h and then left untreated or incubated with ET-1. Cells were then fixed with
3.7% paraformaldehyde (pH 7.4) for 10 min and then permeabilized for 10 min with PBS (Ca^{2+}/Mg^{2+}-free), containing 0.1% Triton X-100. Immunostaining was performed as described previously (12, 23), using polyclonal antibodies to ETA and ETB receptor (1:50), followed by streptavidin-biotin peroxidase complex (LSAB kit; Dako). The specificity of the anti-ETA and ETB receptor antibodies was controlled by preabsorption of the primary antibodies with a membrane preparation from human fetal penile smooth muscle cells (hPSCM), particularly enriched in the respective receptors, as detected by binding experiments (38), according to a previously described method (39). Briefly, ETA and ETB receptor antibodies (working dilution) were incubated with 1 mg/ml hPSCM membranes in 50 mM Tris HCl buffer, or with buffer only, overnight at 4 C. After an additional 60-min incubation with 4% polyethylene glycol, the unbound antibodies were separated by rapid centrifugation and used for immunohistochemistry. Filamentous actin (F-actin) was stained with rhodamine phalloidin (1:50; Molecular Probes, Eugene, OR) in the permeabilization solution for 45 min at room temperature. Cells were viewed with a laser scanner confocal microscope (MRC 600; Bio-Rad, Hercules, CA), equipped with a Nikon (Tokyo, Japan) diaphot inverted microscope or with a Nikon Microphot-FX microscope. The percentages shown in Figure 3 concerning various morphologies of actin-based cell deformations (i.e. percentage of cells showing at least two of the following morphological features: actin patches, filopodia, lamellipodia, and membrane ruffles) were obtained by counting the number of activated cells over the total number of stained cells from three different experiments (at least three slides for each experiment and five fields from each slide).

GnRH and ET-1 RIA

Immunoreactive GnRH was extracted from conditioned media of FNC-B4 cells with chilled absolute ethanol (−20 C), evaporated to dryness, and subjected to RIA using a commercial kit (Buhlmann Laboratories), as described previously (31). Immunoreactive ET-1 was extracted from conditioned media of FNC-B4 cells using Sep-Pak C18 cartridges (Millipore, Millford, MA), as described previously (12). The specific RIA for ET-1 was performed in 0.1 M PBS (0.1% Triton X-100, 0.1% BSA, and 0.01% NaN₃ (pH 7.4)) by a two-step incubation procedure. Samples and standards (0.1 ml) were incubated at 4 C overnight with the respective antiserum (ET-1: RAS6901, 1:20,000, 0.1 ml) and further incubated with the respective tracer (0.1 ml, 10 pM) at 4 C overnight. Bound/free separation was performed by a second antibody/polyethylene glycol procedure.

SDS-PAGE, Western blot analysis, and immunoblotting

FNC-B4 cells, grown to confluence, were scraped into PBS (Ca^{2+}/Mg^{2+}-free), centrifuged, and resuspended in lysis buffer [20 mM Tris-HCl, 150 mM NaCl, 0.25% Nonidet P-40, 1 mM Na₃VO₄, 1 mM phenyl-
methylsulfonylfluoride, 1 mM EGTA (pH 7.4)]. Protein concentration was measured using a Coomassie Bio-Rad protein assay kit. Aliquots containing 30 μg of proteins were diluted in 2× reducing Laemmli’s sample buffer [6.25 mM Tris (pH 6.8), 10% glycerol, 20% SDS, 2.5% pyronin, and 100 mM dithiothreitol] and loaded onto 10% SDS-PAGE. After SDS-PAGE, proteins were transferred to nitrocellulose membranes (Immobilon-P transfer membranes, polyvinylidene difluoride; Millipore). Membranes were blocked overnight at 4°C in 5% BSA-TTBS buffer (0.1% Tween 20, 20 mM Tris-HCl, and 150 mM NaCl), washed in TTBS, and incubated for 2 h with anti-actin primary antibody (1:1000 dilution), followed by peroxidase-conjugated secondary IgG (1:3000). Finally, the reacted proteins were revealed by enhanced chemiluminescence system (ECL; Roche Diagnostics, Basel, Switzerland). For reprobing with different antibodies, the nitrocellulose membranes were washed for 30 min at 50°C in stripping buffer [10 mM Tris (pH 6.8), 2% SDS, 100 mM b-mercaptoethanol] and reprobed with goat IgG antibody (1:100 dilution; sc-7455; Santa Cruz Biotechnology).

**Chemotactic assay**

Cell migration was performed as described previously (27). Briefly, modified Boyden chambers (Nuclepore, Pleasanton, CA), each equipped with a 13-mm diameter and a 5- or 8-μm porosity polycarbonate filter were used. The filters were coated with 20 μg/ml human type I collagen or 10 μg/ml fibronectin (Collaborative Biomedical Products, Bedford, MA) for 30 min at 37°C. Confluent FNC-B4 cells, GN11 cells, and SH-SY5Y cells were incubated in SFM for 24 h (control conditions). After mild trypsinization with 0.05% trypsin-EDTA, in 210-μl aliquots, each of which corresponding to 4 × 10⁴ cells/Boyden chamber, the cells were added to the top wells and incubated at 37°C in 5% CO₂ for 6 h. Increasing concentrations of ET-1, or IRL-1620, in the presence or absence of ETA and/or ETB receptor antagonists (A-BQ123 or B-BQ788; 10⁻⁷ M concentration), and GnRH or buserelin, in the presence or absence of cetrorelix (10⁻⁷ M concentration), were added to the bottom chambers. Both ET-1 and GnRH were incubated in the presence of cetrorelix or A-BQ123/B-BQ788, respectively. After incubation, the migrated cells were fixed in 96% methanol and stained with Diff Quick solution (Biomap, Milan, Italy) or Harris’ hematoxylin solution. Chemotaxis was quantitated by randomly counting six chosen fields per filter, and results were expressed as the number of cells per high-power field (HPF).

**Statistical analysis**

Data are expressed as the mean ± sd. An one-way ANOVA followed by *post hoc* test (Bonferroni’s correction for multiple comparisons) was
performed. The level of \( P < 0.05 \) was accepted as statistically significant. Comparisons of percentages were analyzed statistically after conversion through arc-sine transformation from the binomial to the normal distribution. The computer program ALLFIT was used for the analysis of the sigmoidal dose-response curves (40).

Results

ETB receptor expression in human FNC-B4 cells

Figure 1A (top) shows ETA and ETB mRNA expression (quantitative RT-PCR) in neuronal compared with endothelial cells, taken as positive controls. Both GnRH-secreting neurons and neuroblastoma cells express, respectively, a 4- and 15-fold higher concentration of ETB transcripts than HUVEC, classically considered positive targets for ETB ligands (37). Western blot analysis with polyclonal anti-ETA and anti-ETB antibodies (Fig. 1A, bottom) shows specific bands for both receptors, at the expected molecular weight, in both FNC-B4 or SH-SY5Y cells. The intracellular immunodistribution of ETA and ETB in FNC-B4 cells is shown in Fig. 1B. Note the positivity for both receptors in the perinuclear cytoplasmic compartment, with a fading localization within the tiny cytoplasmic protrusions (Fig. 1B).

Intracellular signaling activated by ET-1 in FNC-B4 cells

A typical experiment on ET-1-induced intracellular calcium mobilization in fura 2-loaded FNC-B4 cells is shown in Figure 2. ET-1 (10^{-7} \text{ m}) induced in control cells a transient and sustained activation of calcium waves. This stimulation was partially blunted by the ETB antagonist B-BQ788, although it was substantially inhibited by the ETA antagonist A-BQ123. Quantitative analysis of multiple results (data not shown) indicated that A-BQ123 inhibits 70 ± 2% and B-BQ788 inhibits 30 ± 3% of the ET-1-induced calcium mobilization. Only the simultaneous presence of both antagonists almost abolished ET-1-stimulated calcium transients (Fig. 2). These results suggest that both receptors are involved in mobilizing intracellular calcium in FNC-B4 cells.

Biological effects of ETB receptor activation in FNC-B4 neurons

Unstimulated FNC-B4 cells showed an intense actin stress fiber network, as detected by F-actin conjugated with rhodamine phalloidin (Fig. 3, CTL). In this assay, a small fraction (10 ± 2%; \( n = 3 \)) of unstimulated cells displayed actin cytoskeletal remodeling. After 18 h of exposure to ET-1 (10^{-7} \text{ m}) (Fig. 3, ET-1), we noticed a significant increase (68 ± 2%; \( n = 3 \); \( P < 0.0005 \); ET-1 vs. control) in various actin-based cell deformations, i.e. actin patches (thin arrow), filopodia (thick arrow), lamellipodia (arrowhead), and membrane ruffles. In addition, we documented an ET-1-induced development of broad lamellae, prominent lamellipodia, numerous membrane ruffles, and microspikes, compatible with a motile phenotype. A-BQ123 (10^{-7} \text{ m}) was ineffective in antagonizing ET-1 effects (65 ± 3%; \( n = 3 \); \( P < 0.005 \)) (Fig. 3, ET-1 + BQ123), whereas B-BQ788 (10^{-7} \text{ m}) was able to elicit ET-1-induced phenotype modifications [15 ± 3%; \( n = 3 \); \( P \) value was not significant (ns)] (Fig. 3, ET-1 + BQ788). These ET-1-induced cytoskeletal rearrangements were further confirmed by Western blot analysis using actin antisemur recognizing actin protein at the expected molecular weight (Fig. 4A). ET-1 induced a significant increase (\( P < 0.023 \)) in actin expression, not reverted (\( P < 0.05 \)) by A-BQ123 but reverted by B-BQ788 (\( P \) value was ns) (Fig. 4B). To assess equal protein loading, nitrocellulose membranes were stripped and reprobed with anti-NSE (we thus observed no significant modifications either after ET-1 exposure or inhibitors’ stimulation in the presence of ET-1) (Fig. 4C). Because ET-1 induced a motile phenotype in FNC-B4 cells, we studied whether or not ET-1 induced cell migration by using the chemotactic Boyden chamber technique (cell migration toward regions at higher concentration of chemotactic factors). FNC-B4 neuronal cells responded in a migratory manner to ET-1 (Fig. 5A). In particular, FNC-B4 responded to SFM with a time-dependent increase in spontaneous random migration (7 ± 1.4 cells per HPF after 6 h of incubation; \( n = 30 \)). ET-1 stimulated a 4- to 6-fold increase in this migratory pattern in the FNC-B4 cells in a dose-dependent manner (from 10^{-9} to 10^{-7} \text{ m} \) (\( n = 12; *, P < 0.0005 \) vs. SFM). Whereas the ETA receptor antagonist A-BQ123 was ineffective to completely counteract ET-1-in
produced migratory pattern (n = 12; *, P < 0.0005 vs. SFM), the ETB receptor antagonist B-BQ788 was able to blunt this effect (P value was ns). The data suggest the main involvement of ETB receptor in the migration of FNC-B4. This was further confirmed by the incubation with an ETB receptor-selective agonist (IRL-1620, 10^{-7} M) (n = 12; *, P < 0.0005 vs. SFM). A representative pattern of migrating cells on the Boyden chamber filters is shown in Figure 5B. In particular, ET-1 induced a migratory pattern characterized by a huge recruitment of cell populations that maintained close connections with one another, which was blunted only by B-BQ788. We also tested the migratory activity of ET-1 in two other cell lines, GN11 and SH-SY-5Y. The immortalized GN11 cells, intrinsically motile like GnRH cells, provided an excellent cellular model of migrating GnRH neurons that are arrested during their transit to the brain. The human neuroblastoma SH-SY-5Y cell line, a clonal derivative from primary tumors of neural crest cells, represented a valid model of the invasive behavior of neural crest cells. Even in these cell lines ET-1 (10^{-7} and 10^{-8} M) induced a strictly ETB-dependent migratory pattern. In fact, in both GN11 (n = 4) and SH-SY5Y (n = 3) cells, ET-1 induced a significant (P < 0.0005) increase in cell migration, which was completely abolished by B-BQ788 but not by A-BQ123 (Fig. 6, A and B).

**Crossstalk of ET-1 and GnRH peptides in FNC-B4 neurons**

The aforementioned results, taken together, strongly suggest that ET-1 induced migration in neural cells and, in particular, in GnRH-producing cells, through ETB receptors. Previous studies have demonstrated that FNC-B4 cells produce and respond to ET-1; this peptide not only positively regulates GnRH secretion (acting through the ETA receptors) but also stimulates proliferation (acting through ETB receptors) (12). GnRH induced in the same cells GnRH release and a clear migratory pattern (27). Now we observed GnRH-induced ET-1 production that is able to elicit FNC-B4 cell migration. The aim of this study was also to investigate whether migration and release due to GnRH were, at least partially, mediated by a GnRH-induced activation of ET-1 signaling. We found that, in FNC-B4 cells, increasing concentrations (10^{-12} to 10^{-6} M) of buserelin, a GnRH agonist, induced a 9-fold increase in ET-1 release (EC_{50} of 0.95 ± 0.17 nM; n = 3) (Fig. 7). To test whether an ET-1-driven autocrine loop was involved in GnRH-induced GnRH secretion, we performed GnRH release experiments in the presence of selective receptor antagonists. As reported previously (12, 27), both buserelin and ET-1 (10^{-7} M) stimulated GnRH secretion (Fig. 8), which was only abolished by their cognate antagonists. In fact, neither the ET-1 antagonists A-BQ123/BBQ788 nor cetorelix affected GnRH secretion induced by buserelin and ET-1, respectively. Interestingly, only A-BQ123 blunted the stimulatory effect of ET-1, thus confirming the involvement of ETA receptors in GnRH secretion (n = 4; *, P < 0.0005 vs. control value = 100%) (12). The specific GnRH antagonist cetorelix (10^{-7} M) blunted GnRH-induced release in the presence of buserelin, although it did not modify
GnRH release in the presence of ET-1 (n = 4; *, P < 0.0005 vs. control) was significant. Similar results were obtained through cell migration. As shown in Fig 9, we observed a higher degree of migratory potency of the ET-1 peptide with respect to the GnRH peptide (a 4- to 6-fold increase with respect to a 3- to 4-fold increase; n = 6; *, P < 0.0005 vs. control conditions). Similar results were observed after stimulation of cells with the GnRH analog buserelin (data not shown). Furthermore, we observed that the ETA receptor antagonist A-BQ123 was ineffective in the presence of either ET-1 (10^{-7} M) (n = 6; *, P < 0.0005 vs. control) or GnRH (at the same concentration) (n = 6; *, P < 0.0005 vs. control) stimulation. However, ETB receptor antagonist B-BQ788, effective in counteracting ET-1 migration (n = 6; *, P values were ns), did not significantly blunt the GnRH-induced migrating capacity (n = 6; *, P < 0.0005 vs. control). Cetrorelix was able to blunt GnRH migration (n = 6; *, P value was ns), although it was ineffective in blunting ET-1-induced migration (n = 6; *, P < 0.0005 vs. control) (Fig. 9).

Discussion

This study is the first to document that human olfactory GnRH-secreting neuroblasts, FNC-B4 cells, are able to migrate in response to ET-1. This ability to migrate was observed also in the immortalized mouse GnRH-expressing neuronal cell line GN11. A striking feature of this report is that ET-1 migration was elicited by selective ETB receptor recruitment and was completely independent of the previously reported ETA-induced GnRH secretion (12). Primary human GnRH-secreting neuroblasts FNC-B4, established from fetal olfactory epithelium, and immortalized GnRH-expressing neuronal cell line GN11, isolated from an olfactory tumor of migration-arrested GnRH neurons, retain properties found in vivo in either the early or the later stages of GnRH neuronal navigation (27, 29, 31, 41, 42). Thus, these cell lines represent excellent models to study prenatal GnRH neurons. The results herein presented show that ET-1 recruitment is due to ETB receptor activation. By using ETB receptor antagonist B-BQ788, a significant inhibition of ET-1-induced migration was observed. FNC-B4 cells present two different binding receptors, i.e. the ETA and ETB receptors. These two classes of molecules are involved in different biological responses. ETA receptor recruitment induced GnRH secretion, whereas ETB receptor stimulated DNA synthesis (12). In this report, we show that ET-1, through ETB receptor recruitment, was able to trigger a striking morphological activation of cells toward a clear migratory pattern and intracellular calcium increase. ET-1 induced modifications in cell shape and development of cytoplasmic protrusions and lamellipodia extensions, associated with actin protein expression. This recruitment led to the formation of a huge intercellular network, which probably constituted the morphological basis of cell activation and the consequent induction of multiple intercellular crosstalks (3).
express ET-1 and respond to ET-1 through a GnRH release, which, in turn, was able to induce FNC-B4 cells to migrate (12, 27). Here, we demonstrate that GnRH stimulated ET-1 release. Because ET-1 stimulated motility and GnRH release, we investigated whether these GnRH-related effects may be, at least partially, mediated by a GnRH-induced activation of ET-1 signaling. Our findings suggest a crosstalk between these two neuropeptides. In fact, functional data, by using selective antagonists, indicate that FNC-B4 cells were independently and selectively stimulated by the two different peptides. Thus, ET-1, through ETA/ETB and GnRH receptor crossstalk, may participate in differentiation of the neuroendocrine phenotype of FNC-B4 olfactory neuroblasts.

In the olfactory epithelium, proliferation of neural precursor cells and differentiation of their progeny into olfactory receptor neurons begin during embryogenesis and continue throughout life (43, 44). The ET-3/ETB pathway has the potential to differentiate neural crest cells to multipotent precursors (45–47). Thus, exposure of FNC-B4 neuroblasts to ET-1 may lead to different stages of differentiation of functional activation. The first one is characterized by an immature and undifferentiated stage, with a huge proliferative commitment, and the second one, more differentiated, is characterized by morphological and cytoskeletal activation, the acquisition of clear chemotactic properties, and the recruitment of both subtypes of ET and GnRH receptors. These receptors, together with functional recruitment of both GnRH and ET-1 molecules, are able to crossstalk and interact with each other (the so-called “loop activity between ET and GnRH”). We suggest that the onset of this activity loop plays a critical role in the differentiation of FNC-B4 olfactory neuroblasts.

**FIG. 8.** Effects of ET-1 and GnRH agonists and antagonists on GnRH release from FNC-B4 cells. ET-1 (10^{-7} M) and buserelin (10^{-7} M) induced 3-fold and 4-fold increase, respectively, in GnRH secretion (both *, P < 0.0005 vs. control). ET-1 stimulation on GnRH release was unaffected by BQ788 (10^{-7} M; *, P < 0.0005 vs. control) and cetrorelix (10^{-7} M; *, P < 0.0005 vs. control) but almost completely blunted by BQ123 (10^{-7} M). Buserelin stimulation was unaffected by both ET-1 antagonists (both *, P < 0.0005 vs. control) but completely abrogated by cetrorelix. Columns indicate the percentage of increase in GnRH secretion over the control value (100%), as measured by RIA. Experiments were done in triplicate. CTL, Control.

**FIG. 9.** Effects of ET-1 and GnRH agonists and antagonists on FNC-B4 migration. ET-1 (10^{-7} M) and buserelin (10^{-7} M), with or without BQ123, BQ788, or cetrorelix (10^{-7} M), were added to the bottom chambers. ET-1 and GnRH elicited a sustained increase in migration (both *, P < 0.0005 vs. control). ET-1 effect was completely blocked by BQ788 but not by BQ123 and cetrorelix (both *, P < 0.0005 vs. control). GnRH-induced migration was completely countered by cetrorelix but not by the two ET-1 antagonists (both *, P < 0.0005 vs. control). Experiments were performed in triplicate. CTL, Control.
a role underlying the development of the specialized neuroendocrine cells as they migrate through nasal regions.

Maggi et al. (12) have shown that, during early embryonic life, ET-1 gene and protein, as well as endothelin-converting enzyme-1, are present in cells in theolfactory epithelium. From these data, together with our in vitro data, we speculate that, in the in vitro situation, ET-1 interacts with growth and differentiating factors not only to maintain a reservoir of GnRH-secreting neural cells but also to stimulate cell migration and a fully activated phenotype. Therefore, ET-1 could play a role in both guiding GnRH-secreting human neurons during their migration and orchestrating their subsequent differentiation.

During early embryogenesis, brain areas that undergo rapid neurogenic development and migration of cells through a differentiating matrix require very high energy for nutrients and the disposal of waste products. These requirements are best met by a rich blood supply. These needs constitute a possible trigger for the development of an elaborated “cellulo-vascular bridge” from the placode epithelium across the nasal septum and into the ventromedial forebrain (48). A close association between these angiogenic mechanisms and migration of GnRH neurons has been reported in embryonic mice, in early stage human embryos, and in those fetuses affected by Kallmann’s syndrome (48). Angiogenesis is an important early event not only in normal development but also in tumor progression, beginning in premalignant lesions (49). The endothelin system represents one of the most studied growth factor families that has been involved in modulating angiogenesis (50). Moreover, a close association between the loss of ETB receptor mRNA expression and the onset of a metastatic phenotype of neuroblastoma tumors, strictly associated with the disease progression, has been described previously (51). The blunted migration observed through specific ETB receptor mRNA expression and the onset of a metastatic phenotype of neuroblastoma tumors, strictly associated with the disease progression, has been described previously (51). The blunted migration observed through specific ETB receptor mRNA expression and the onset of a metastatic phenotype of neuroblastoma tumors, strictly associated with the disease progression, has been described previously (51).

We thus hypothesize that ETB receptor signaling may be required in vivo conditions to maintain a mature neuronal differentiation. Additional studies are needed to clarify whether the loss of ETB receptor expression during development can represent one of the underlying molecular mechanisms for both the hypogonadotropic hypogonadism as well as the onset of olfactory-derived tumors.

Acknowledgments
We thank Prof. Vieri Boodi for his helpful supervision in statistical analysis.

Received January 14, 2005. Accepted June 15, 2005.

Address all correspondence and requests for reprints to: Gabriella B. Vannelli, Department of Anatomy Histology and Forensic Medicine, University of Florence, School of Medicine, V. le Morgagni 85, I-50134 Florence, Italy. E-mail: vannelli@unifi.it.

This work was supported by grants from the Ministero dell’Istruzione, dell’Università e della Ricerca, Telethon (number E523), and the University of Florence.

References
10. Moretto M, Lopez FJ, Vegiro-Vilar A 1993 Endothelin-3 stimulates luteinizing hormone-releasing hormone (LHRH) secretion from LHRH neurons by a prostanoid-dependent mechanism. Endocrinology 132:769–784
25. Barlow A, de Graaff E, Pachnis V 2003 Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET. Neuro 40:905–916
27. Romaneli RG, Barni T, Maggi M, Luconi M, Failli P, Pezzatini A, Pelo E,